The study is a multi-center, prospective, non-interventional and observational study, and will collect data on the safety and efficacy of Tyvyt® in the treatment of Chinese patients with relapsed or refractory classical Hodgkin's lymphoma.
Study Type
OBSERVATIONAL
Enrollment
300
Peking Union Medical College Hospital
Beijing, China
RECRUITINGIncidence of known adverse drug reactions
Time frame: During the actual Tyvyt treatment time.
Occurrence of new adverse drug reactions
Time frame: During the actual Tyvyt treatment time.
Association, risk factors, severity and incidence of immune-related adverse drug reactions/events
Time frame: During the actual Tyvyt treatment time.
Association, risk factors, severity and incidence of serious adverse drug reactions
Time frame: During the actual Tyvyt treatment time.
Occurrence of adverse drug reactions in special population
Time frame: During the actual Tyvyt treatment time.
Overall survival (OS)
Time frame: During the actual Tyvyt treatment time.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.